A Phase 1 interventional study of SC HYLENEX and Ceftriaxone and SC Placebo and Ceftriaxone in Healthy, sponsored by Baxter Healthcare Corporation. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-02.
Sponsored by Baxter Healthcare Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are:
Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
Drug: SC HYLENEX and Ceftriaxone · Drug: SC Placebo and Ceftriaxone · Drug: IV Ceftriaxone
Drug page: Hyaluronoglucosaminidase
single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Also known as: HYLENEX recombinant, hyaluronoglucosaminidase, hyaluronidase, rHuPH20
single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Also known as: saline, normal saline, 0.9% sodium chloride injection
single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
Also known as: ceftriaxone
AUC0-t
Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)
Time frame: Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration
AUC0-inf
Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)
Time frame: from the start of ceftriaxone administration to infinity
Cmax
Maximum measured plasma ceftriaxone concentration
Time frame: at the time of the highest measured plasma ceftriaxone concentration
Tmax
Time to maximum measured plasma ceftriaxone concentration
Time frame: from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration
Healthy volunteers recruited via subject-initiated telephone or internet contacts or visits to Phase I unit. Those considered potentially eligible were, after obtaining consent, screened in detail to determine eligibility against protocol eligibility criteria.
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 4 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC |
|---|---|---|---|---|---|---|
| Started | 4 | 5 | 5 | 5 | 5 | 5 |
| Completed | 4 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum measured plasma ceftriaxone concentration
| µg/mL | HYLENEX SC | Placebo SC | Intravenous |
|---|---|---|---|
| Cmax | 92.0 ± 15.1 | 82.2 ± 13.5 | 150 ± 19.9 |
Time to maximum measured plasma ceftriaxone concentration
| hr | HYLENEX SC | Placebo SC | Intravenous |
|---|---|---|---|
| Tmax | 2.02 (1.02 to 3.01) | 3.02 (1.52 to 4.04) | 0.502 (0.501 to 0.611) |
Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)
| μg*hr/mL | HYLENEX SC | Placebo SC | Intravenous |
|---|---|---|---|
| AUC0-t | 1139.3 ± 200.30 | 1115.6 ± 180.55 | 1065.3 ± 176.07 |
Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)
| µg*hr/mL | HYLENEX SC | Placebo SC | Intravenous |
|---|---|---|---|
| AUC0-inf | 1162.6 ± 210.36 | 1141.3 ± 192.86 | 1085.8 ± 187.50 |
Collected over from time of start of intervention administration through 7 days after intervention administered. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HYLENEX SC | — | 0/30 (0%) | 30/30 (100%) |
| Placebo SC | — | 0/30 (0%) | 30/30 (100%) |
| Intravenous | — | 0/29 (0%) | 22/29 (75.9%) |
| Event | HYLENEX SC | Placebo SC | Intravenous |
|---|---|---|---|
| Infusion site painGeneral disorders | 30/30 | 30/30 | 9/29 |
| Infusion site swellingGeneral disorders | 5/30 | 28/30 | 1/29 |
| Infusion site erythemaGeneral disorders | 18/30 | 15/30 | 4/29 |
| Infusion site bruisingGeneral disorders | 2/30 | 4/30 | 6/29 |
| Infusion site reactionGeneral disorders | 6/30 | 0/30 | 0/29 |
| Infusion site anaesthesiaGeneral disorders | 4/30 | 1/30 | 0/29 |
| HeadacheNervous system disorders | 2/30 | 3/30 | 0/29 |
| Infusion site pruritusGeneral disorders | 2/30 | 0/30 | 2/29 |
| Vessel puncture site bruiseGeneral disorders | 1/30 | 2/30 | 2/29 |
| Infusion site indurationGeneral disorders | 2/30 | 1/30 | 0/29 |
| Age, Categorical(Participants) | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 5 | 5 | 5 | 5 | 5 | 30 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(years) | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC | Total |
|---|---|---|---|---|---|---|---|
| Mean | 32.2 ± 10.6 | 37.6 ± 4.0 | 34.2 ± 11.5 | 34.8 ± 17.5 | 34.8 ± 11.0 | 33.2 ± 8.0 | 34.5 ± 10.3 |
| Sex: Female, Male(Participants) | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 1 | 2 | 0 | 5 |
| Male | 4 | 5 | 4 | 4 | 3 | 5 | 25 |
| Region of Enrollment(participants) | HYLENEX SC, Placebo SC, IV | HYLENEX SC, IV, Placebo SC | Placebo SC, HYLENEX SC, IV | Placebo SC, IV, HYLENEX SC | IV, HYLENEX SC, Placebo SC | IV, Placebo SC, HYLENEX SC | Total |
|---|---|---|---|---|---|---|---|
| United States | 5 | 5 | 5 | 5 | 5 | 5 | 30 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hyaluronoglucosaminidase · Ceftriaxone
Baxter Healthcare Corporation →